Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sanofi (GB:0O59)
LSE:0O59
Holding GB:0O59?
Track your performance easily
0O59 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€77.73 - €106.14
Previous Close€95.84
Volume124.70K
Average Volume (3M)726.06K
Market Cap
€120.66B
Enterprise Value€129.82B
Total Cash (Recent Filing)$8.71B
Total Debt (Recent Filing)$18.15B
Price to Earnings (P/E)28.4
Beta0.46
Next Earnings
Jan 30, 2025EPS Estimate
€1.61Last Dividend Ex-Date
May 13, 2024Dividend Yield3.94%
Share Statistics
EPS (TTM)3.37
Shares Outstanding1,252,640,466
10 Day Avg. Volume570,738
30 Day Avg. Volume726,061
Standard Deviation0.06
R-Squared0.21
Alpha0.00537
Financial Highlights & Ratios
Price to Book (P/B)3.23
Price to Sales (P/S)3.87
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.44
Enterprise Value/Gross Profit4.03
Enterprise Value/Ebitda25.19
Forecast
1Y Price Target
€112.34Price Target Upside17.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Sanofi News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company delivered a broad beat in its third quarter results, reinforcing a positive outlook.
Product Efficacy And SafetyBeyfortus is an approved, ACIP-recommended and established product with a demonstrated high level of efficacy on both reduction in infections and hospitalization in both clinical trials and impressive real-world studies combined with 'pristine' safety.
Strategic Asset ManagementSanofi's sale of a 50% stake in its CHC business Opella is strategically sensible, monetizing a slow-growing asset and leaving shareholders exposed to faster growth in Sanofi's biopharma business.
Bears Say
Clinical TrialsTolebrutinib failed to show superiority over Aubagio in the Ph3 GEMINI 1 and 2 RMS trials, which shows a high bar for approval.
EarningsThe sale of Opella will lead to a pro-forma business EPS dilution of 10.6%, which cannot be totally offset even with a buyback.
Product EfficacyRocatinlimab efficacy was underwhelming, demonstrating worse efficacy than seen with Sanofi’s Dupixent.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
12.45% Mutual Funds
<0.01% Other Institutional Investors
73.29% Public Companies and
Individual Investors
0O59 FAQ
What was Sanofi’s price range in the past 12 months?
Sanofi lowest share price was €77.73 and its highest was €106.14 in the past 12 months.
What is Sanofi’s market cap?
Currently, no data Available
When is Sanofi’s upcoming earnings report date?
Sanofi’s upcoming earnings report date is Jan 30, 2025 which is in 78 days.
How were Sanofi’s earnings last quarter?
Sanofi released its earnings results on Oct 25, 2024. The company reported €2.86 earnings per share for the quarter, beating the consensus estimate of €2.482 by €0.378.
Is Sanofi overvalued?
According to Wall Street analysts Sanofi’s price is currently Undervalued.
Does Sanofi pay dividends?
Sanofi pays a Annually dividend of €3.76 which represents an annual dividend yield of 3.94%. See more information on Sanofi dividends here
What is Sanofi’s EPS estimate?
Sanofi’s EPS estimate is €1.61.
How many shares outstanding does Sanofi have?
Sanofi has 1,268,922,700 shares outstanding.
What happened to Sanofi’s price movement after its last earnings report?
Sanofi reported an EPS of €2.86 in its last earnings report, beating expectations of €2.482. Following the earnings report the stock price went up 0.675%.
Which hedge fund is a major shareholder of Sanofi?
Currently, no hedge funds are holding shares in GB:0O59
---
Sanofi Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.10%
12-Months-Change
Fundamentals
Return on Equity
5.80%
Trailing 12-Months
Asset Growth
1.69%
Trailing 12-Months
Company Description
Sanofi
Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes & cardiovascular, established prescription products and generics, together with research, development and production activities. This segment also includes all associates whose activities are related to pharmaceuticals. The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for its Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines. The company was founded in 1973 and is headquartered in Paris, France.
---
0O59 Company Deck
---
0O59 Earnings Call
Q3 2024
0:00 / 0:00
---
0O59 Stock 12 Month Forecast
Average Price Target
€112.34
▲(17.21% Upside)
Technical Analysis
Best Analysts Covering 0O59
1 Year
1 Year Success Rate
27/38 ratings generated profit
1 Year Average Return
+4.96%
assigned a buy rating 22 days ago
Copying Peter Welford's trades and holding each position for 1 Year would result in 71.05% of your transactions generating a profit, with an average return of +4.96% per trade.
---